Search
Search Results
##search.searchResults.foundPlural##
-
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
397PDF: 360Suppl. Files: 52HTML: 22 -
HOMOZYGOUS DELETION ALFA-THALASSEMIA AND HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, TWO GENETIC FACTORS PREDICTIVE THE REDUCTION OF MORBIDITY AND MORTALITY DURING PREGNANCY IN SICKLE CELL PATIENTS . A REPORT FROM DEMOCRATIC REPUBLIC OF CONGO ALPHA THALASSEMIA AND HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN REDUCE MORBIDITY DURING PREGNANCY IN SICKLE CELL PATIENTS
10032PDF: 997HTML: 227 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
91PDF: 73HTML: 13 -
QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
1415PDF: 693HTML: 1382cover letter: 214 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4837PDF: 1796HTML: 2723Untitled: 227 -
The association of rheumatoid arthritis with glucose- 6-phosphate dehydrogenase deficiency—results from a case-control study. G6PD and Rheumatoid Arthritis
1147PDF: 861HTML: 107 -
DONOR KIR3DL1/RECEPTOR HLA-BW4-80I COMBINATION REDUCES ACUTE LEUKEMIA RELAPSE AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION KIR3DL1 with HLA-Bw4-80I reduces leukemia relapse
1402PDF: 549HTML: 209 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1210PDF: 929HTML: 291 -
MENDELIAN SUSCEPTIBILITY TO MYCOBACTERIAL DISEASE IN EGYPTIAN CHILDREN
1823PDF: 850HTML: 1154Cover: 185 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
863PDF: 490HTML: 1308 -
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients
1005PDF: 368HTML: 208 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
3943PDF: 1495HTML: 8520 -
CD48 AS A NOVEL EARLY BIOMARKER COMPLEMENTING PROCALCITONIN AND LACTATE FOR PREDICTING BACTEREMIA IN PEDIATRIC FEBRILE NEUTROPENIA: A PROSPECTIVE COHORT STUDY CD48 A NOVEL EARLY BIOMARKER PREDICTING BACTERIEMIA
904PDF: 676HTML: 114 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1998PDF: 731HTML: 688Table1: patient's characteristics: 160Table 2: profile of each patient: 184 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
740PDF: 472HTML: 6272 -
PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome
1129PDF: 776HTML: 318 -
DIAGNOSTIC VALUE OF SIMULTANEOUS MEASUREMENT OF PROCALCITONIN, INTERLEUKIN-6 AND HS CRP IN PREDICTION OF EARLY-ONSET NEONATAL SEPSIS
2074PDF: 1223HTML: 1937Untitled: 153TaBles Neinates sepsis: 178 -
THE EFFECT OF ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA. ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS
2720PDF: 992HTML: 77 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2799PDF: 1132HTML: 3294 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1729PDF: 1201HTML: 235 -
Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
1435PDF: 834HTML: 1032Untitled: 190 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3976PDF: 762HTML: 1854 -
PREVENTION OF POST-TRANSFUSION HEPATITIS BY SCREENING OF ANTIBODY TO HEPATITIS B CORE ANTIGEN IN HEALTHY BLOOD DONORS
1178PDF: 696HTML: 1256Title page: 209 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2437PDF: 1601HTML: 649 -
APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
2597PDF: 980HTML: 15118







